Aficamten, a second generation myosin inhibitor, was administered to a small group of 28 patients as part of a phase 2 trial to determine safety of the drug of the drug in obstructive HCM over a 10 week period.
No safety issues were found, while most trial participants experienced substantial reductions in left ventricular outflow tract gradients. Study participants also reported improvement to their symptoms, while blood tests showed improvement to certain biomarkers of heart stress.
You can read more about the drug aficamten and Cytokinetics, the company behind it, in the below posts on HCMBeat. Next for aficamten is the Phase 3 trial entitled SEQUOIA-HCM.
Promising Data about Aficamten Presented at Meetings
2 Companies Testing Drugs for HCM
HCM Clinical Trials – the Latest News
Positive Signs from REDWOOD-HCM
Cytokinetic’s Drug Aficamten & Upcoming HCM Summit – Interview with Dr. Martin Maron
Aficamten Gets “Breakthrough Drug” Status from FDA
More on Aficamten & Mavacamten from ACC 2022
Cytokinetics Announces its Phase 2 Clinical Trial – “Redwood-HCM”
Cytokinetics Moves Forward with HCM Drug Trial
Cytokinetics Announces Positive Results from REDWOOD-HCM Phase 2 Clinical Trial
HCM Beat 
One thought on “Results Published from REDWOOD-HCM Phase 2 Trial”